Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 5880-5895

  Eldrup, Anne B ^a   Soleymanzadeh, Fariba ^a   Taylor, Steven J ^a   Muegge, Ingo ^a   Farrow, Neil A ^a   Joseph, David ^a   McKellop, Keith ^a   Man, Chuk C ^a   Kukulka, Alison ^a   De Lombaert, Stéphane ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYANO N [3 (4 FLUOROPHENYL) 3 (4 METHANESULFONYLPHENYL)PROPYL]BENZAMIDE; 4 CYANO N [3,3 BIS (4 FLUOROPHENYL)PROPYL]BENZAMIDE; AROMATIC AMIDE; EPOXIDE HYDROLASE; N (3,3 DIPHENYLPROPYL)ISONICOTINAMIDE; N (3,3 DIPHENYLPROPYL)NICOTINAMIDE; N [3 (4 FLUOROPHENYL) 3 (4 METHANESULFONYLPHENYL)PROPYL] 6 HYDROXYNICOTINAMIDE; N [3 (4 FLUOROPHENYL) 3 (4 METHANESULFONYLPHENYL)PROPYL]4 METHANESULFONYL BENZAMIDE; N [3 (4 FLUOROPHENYL) 3 (4 METHANESULFONYLPHENYL)PROPYL]6 (2,2,2 TRIFLUOROETHOXY)NICOTINAMIDE; N [3 (4 FLUOROPHENYL) 3 (4 METHANESULFONYLPHENYL)PROPYL]NICOTINAMIDE; N [3,3 BIS (4 FLUOROPHENYL)PROPYL] 4 METHANESULFONYLBENZAMIDE; N [3,3 BIS(4 FLUOROPHENYL)PROPYL] 2 (2,2,2 TRIFLUOROETHOXY)ISONICOTINAMIDE; N [3,3 BIS(4 FLUOROPHENYL)PROPYL] 6 (2,2,2 TRIFLUOROETHOXY)NICOTINAMIDE; N [3,3 BIS(4 FLUOROPHENYL)PROPYL]BENZAMIDE; N [3,3 BIS(4 FLUOROPHENYL)PROPYL]NICOTINAMIDE; N [4,4 BIS(4 FLUOROPHENYL)PROPYL] 6 HYDROXYNICOTINAMIDE; PYRIDINE 2 CARBOXYLIC ACID (4,4 DIPHENYLPROPYL)AMIDE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HALF-LIFE; HUMANS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NIACINAMIDE; RATS; SOLUBILITY;

EID: 70349645986     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9005302     Document Type: Article

References (27)

1. Larsen, B. T.; Campbell, W. B.; Guttermann, D. B. Beyond Vasodilation: Nonvasomotor Roles of Epoxyeicosatrienoic Acids in the Cardiovascular System. Trends Pharmacol. Sci. 2007, 28 (1), 32-38.
2. Spector, A. A.; Norris, A. N. Action of Epoxyeicosatrienoic Acids on Cellular Function. Am. J. Cell Physiol. 2007, 292, 996-1012.
3. Schmelzer, K. R.; Inceoglu, B.; Kubala, L.; Kim, I.-H.; Jinks, S. L.; Eiserich, J. P.; Hammock, B. D. Enhancement of Antinociception by Coadministartion of Nonsteroidal Anti-inflammatory Drugs and Soluble Epoxide Hydrolase Inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (37), 13646-13651.
4. Yu, Z.; Xu, F.; Huse, L. M.; Morriseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble Epoxide Hydrolase regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids. Circ. Res. 2000, 87, 992-998.
5. Fang, X.; Weintraub, N. L.; McCaw, R. B.; Hu, S.; Harmon, S. D.; Rice, J. B.; Hammock, B. D.; Spector, A. A. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am. J. Physiol. 2004, 287, 2412-2420.
6. Spector, A. A.; Fang, X.; Snyder, G. D.; Weintraub, N. L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 2004, 43, 55-90.
7. Dorrance, A. M.; Rupp, N.; Pollock, D. M.; Newman, J. W.; Hammock, B. D.; Imig, J. D. An epoxide hydrolase inhibitor 12-(3-Adamantan-1-yl-ureido) dodecanoic acid (AUDA) reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharm. 2005, 46, 842-848.
8. Olearczyk, J. J.; Field, M. B.; Kim, I.-H.; Morisseau, C.; Hammock, B. D.; Imig, J. D. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J. Pharm. Exp. Ther. 2006, 318, 1307-1314.
9. Zhao, X.; Yamamoto, T.; Newman, J. W.; Kim, I.-H.; Watanabe, T.; Hammock, B. D.; Stewart, J.; Pollock, J. S.; Pollock, D. M.; Imig, J. D. Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage. J. Am. Soc. Nephrol. 2004, 15, 1244-1253.
10. Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. U.S. A. 1999, 96, 8849-8854.
11. Kim, I.-H.; Morisseau, C.; Watanabe, T.; Hammock, B. D. Design, Synthesis and Biological Activity of 1,3-Disubstituted Ureas as Potent Inhibitors of Soluble Epoxide Hydrolase of increased water solubility. Optimization of Amide-Based Inhibitors of Soluble Epoxide Hydrolase with Improved Water Solubility. J. Med. Chem. 2004, 47, 2110-2122.
12. Kim, I.-H.; Heirtzler, F. R.; Morisseau, C.; Nishi, K.; Tsai, H.-J.; Hammock, B. D. Optimization of Amide-Based Inhibitors of Soluble Epoxide Hydrolase with Improved Water Solubility. J. Med. Chem. 2005, 48, 3621-3629.
13. Kim, I.-H.; Tsai, H.-J.; Nishi, K.; Kasagami, T.; Morisseau, C.; Hammock, B. D. 1,3-Disubstituted Ureas Functionalized with Ether Groups are Potent Inhibitors of the Soluble Epoxide Hydrolase with Improved Pharmacokinetic Properties. J. Med. Chem. 2007, 50, 5217-5226.
14. Hwang, S. H.; Tsai, H.-J.; Liu, J.-Y.; Morisseau, C.; Hammock, B. D. Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors. J. Med. Chem. 2007, 50, 3825-3840.
15. Caldirola, P. M.; van der Goot, H.; Timmerman, H. New prenylamine analogs: synthesis and calcium(2+)-entry blocking activity Eur. J. Med. Chem. 1992, 27, 571-579.
16. Miyano, S.; Tatsuoka, T.; Suzuki, K.; Imao, K.; Satoh, F.; Ishihara, T.; Hirotsu, I.; Kihara, T.; Hatta, M.; et al. The synthesis and antilipidperoxidation activity of 4,4-diarylbutylamines and 4,4- diarylbutanamides. Chem. Pharm. Bull. 1990, 38, 1570-1574.
17. Buschauer, A.; Friese-Kimmel, A.; Baumann, G.; Schunack, W. Synthesis and histamine H2 agonistic activity of arpromidine analogs: replacement of the pheniramine-like moiety by nonheterocyclic groups. Eur. J. Med. Chem. 1992, 27, 321-1230
18. Taylor, S. J.; Netherton, M. R. Synthesis of the Benzhydryl Motif via a Suzuki-Miyaura Coupling of Arylboronic Acids and 3-Chloroacrylonitriles. J. Org. Chem. 2006, 71, 397-400.
19. Muegge, I.; Rarey, M. Small Molecule Docking and Scoring. In Reviews in Computational Chemistry; Boyd, D. B., Lipkowitz, K. B., Eds.; Wiley-VCH: New York, 2001; Vol 17, pp 1-60,
20. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Baht, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acid Res. 2000, 28, 235-242.
21. Hao, M.-H.; Haq, O.; Muegge, I. Torsion Angle Preferences and Energetic of Small-Molecule Ligands Bound to Proteins. J. Chem. Inf. Model. 2007, 47, 2242-2252.
22. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Structure of Human Epoxide Hydrolase Revels Mehanistic Inferences on Bifuctional Catalysis in Epoxide and phosphate Ester Hydrolysis. Biochemistry 2004, 43, 4716-4723.
23. Argiriadi, M. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Detoxification of environmental mutagens and carcinogens: structure, mechanism and evolution of liver epoxide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10637-10642.
24. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci. 2006, 15, 58-64.
25. Argiriadi, M. A.; Morisseau, C.; Goodrow, M. H.; Dowdy, D. L.; Hammock, B. D.; Christianson, D. W. Binding of Alkyurea Inhibitors to Epoxide Hydrolase Implicates Active Site Tyrosines in Substrate Activation. J. Biol. Chem. 2000, 275, 15265-15270.
26. Friesner, R. A.; et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
27. Jaguar, version 6.5; Schrodinger LLC: New York, 2006.